|
Match
|
Document |
Document Title |
|
|
7547441 |
PAI-2 conjugates for the treatment and imaging of cancer
A method is described for detecting, visualizing, or treating cells, particularly cancerous cells, that express a uPA/uPAR complex. The method employs a PAI-2 conjugate molecule that comprises...
|
|
|
7223730 |
Antithrombosis enzyme from the snake venom of agkistrodon acutus
This invention features an antithrombosis enzyme extracted and purified from the snake venom of Southern-Anhui Agkistrodon acutus and pharmaceutical uses thereof.
|
|
|
7056887 |
Treatment of acute coronary syndrome with GLP-1
The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a...
|
|
|
7018659 |
Anti-arrhythmic pharmaceutical composition and a process thereof
The present invention relates to an anti arrhythmic pharmaceutical comprising effective amount of compound designated as KCV-CAF obtained from the venom of Indian snake King Cobra Ophiophagus...
|
|
|
6833131 |
Antivenom immunesera
An antivenom comprising a mixture of monospecific antisera each raised against venoms of one species or sub-species is disclosed. Also disclosed is a pharmaceutical composition comprising the...
|
|
|
6613324 |
Adhesive for the gluing of biological tissues
Disclosed is an adhesive for gluing of biological tissue, in particular human body tissue. The adhesive contains fibrinogen, a substance capable of supplying calcium ions, blood-coagulating factor...
|
|
|
6489451 |
Antithrombosis enzyme from the snake venom of agkistrodon acutus
This invention features an antithrombosis enzyme extracted and purified from the snake venom of Southern-Anhui Agkistrodon acutus and pharmaceutical uses thereof.
|
|
|
6399576 |
Method of inhibiting apoptosis
A method of inhibiting apoptosis, comprising administering an effective ingredient batroxobin.
|
|
|
6106830 |
Methods for the treatment of apoptosis-related diseases by batroxobin
A pharmaceutical composition for prophylaxis and/or treatment of apoptosis-related diseases which comprises as an effective ingredient batroxobin.
|
|
|
5904922 |
Treatment with polyvalent antivenom containing immunoglobulin which is greater than 50% venom-reactive
Antivenoms to snake, spider, scorpion and jelly fish venoms are produced for treatment of humans and animals, and for analytical use. Polyvalent antivenoms are produced containing immunoglobulin...
|
|
|
5869044 |
Method for the treatment or prophylaxis of ischemia-reperfusion injury
Medicaments for the treatment or prophylaxis of ischemia-reperfusion injury in myocardial ischemia and cerebral ischemia, characterized in that the medicament contains batroxobin as an effective...
|
|
|
5817309 |
Antidote for hirudin and synthetic thrombin inhibitors and method of use
The invention relates to an antidote for hirudin and synthetic thrombin inhibitors; the antidote contains a compound that splits prothrombin into meizothrombin, a prothrombin intermediate, a...
|
|
|
5705198 |
Test for lupus anticoagulant
It was found that the use of a phospholipid dependent prothrombin activator purified from the venom of snakes belonging to the Elapidae family, especially members of the Oxyaranus and Psuedonaja...
|
|
|
5695751 |
Enhancing delivery of large neutral amino acid drugs
L-amino acid oxidase is utilized to reduce the plasma level of large neutral amino acids to allow the opportunity of increased large neutral amino acid drug transport across the blood brain...
|
|
|
5679350 |
Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
A method of delivering a medicament to the surface of a cancer cell and transferring the medicament into the cancer cell using an activated plasminogen activator material such as a plasminogen...
|
|
|
5676974 |
Pharmaceutical compositions containing giroxina and phospholipase A.sub.2 and methods of increasing a patient's CD.sub.4 count using the pharmaceutical compositions
Pharmaceutical compositions for treatment of humans suffering from the symptoms of acquired immune deficiency syndrome (AIDS) or its precursors, lymphadenopathy syndrome (LAS) or AIDS-related...
|
|
|
5562907 |
Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
Human-derived or human-compatible antitoxins are administered is an adjunct to therapy with a toxin, such as botulinum toxin or an immunotoxin, or as an adjunct to therapy with a combination of...
|
|
|
5562899 |
Medical prevention of lacerations to the vagina and perineum
A common complication of vaginal delivery is the tearing of the muscles of the vagina and perineum. This tearing results in an irregular laceration which the surgeon must then repair. Current...
|
|
|
5453370 |
Method for the preparation of a phospholipid-dependent prothrombin activator from the venom of snakes
A method for the preparation of a phospholipid-dependent prothrombin activator from the venom of snakes belonging to the Elapidae family, the activator comprising an increased plasma clotting...
|
|
|
5232911 |
Mixture of a non-covalent heterodimer complex and a basic amphiphatic peptide as cytotoxic agent
Novel cytotoxic agent useful against malignant tumors. It provides a stable composition of matter based on the cytotoxic activity of two synergistically acting toxins which sequence are herein...
|
|
|
5178864 |
Lipoprotein removal by soluble enzymes
A therapeutically effective amount of soluble phospholipase A 2 is administered into a subject for lowering the low density lipoproteins ("LDL") in the blood. Phospholipase A 2 modifies the...
|
|
|
5164196 |
Crotoxin complex as cytotoxic agent
The present invention provides a stable composition of matter based on the cytotoxic activity of a basic phospholipase A 2 of molecular weight 14,500 and isoelectric point 9.6-9.7 (crotoxin B)...
|
|
|
5013555 |
Agent for desensitizing man and/or animals against an allergen
An agent for desensitization of man and/or animals against an allergen comprising liposomes that comprise the allergen is provided together with a method for inducing desensitization by...
|
|
|
5006512 |
Therapeutic usages of inhibitors for a potassium efflux channel
The invention provides novel therapeutic usages of inhibitors of a potassium channel of the cells. Since the increase of the intracellular calcium concentration is known to trigger various...
|
|
|
4849403 |
Protein C activator, methods of preparation and use thereof
A method and composition for assaying protein C is described. The method comprises reacting a protein C-containing medium with a protein C-activating activator preparation obtained from venom of...
|
|
|
4806346 |
Method for isolation of antigen specific immunoglobulin
A process for preparing the purified F(ab) 2 fragment of equine Ig(T) from horses hyperimmunized with snake venom which comprises: (a) passing crude diluted hyperimmune equine serum contianing...
|
|
|
4741902 |
Compositions for treatment of neurological and related disorders
The invention provides compositions of matter having pharmacological activity and which are useful in the treatment of the symptoms of neurological and other disorders, particularly those disorders...
|
|
|
4610879 |
Fibrinolytic enzyme from snake vernom
A protease moiety having direct fibrinolytic activity which is useful in thrombolytic therapy is isolated from snake venom and shown to comprise a metalloproteinase having a molecular weight of...
|
|
|
4585653 |
Neuraminidase treated ancrod
Disclosed is a pharmaceutically effective agent and method of use, comprising ancrod which has been incubated with neuraminidase. The neuraminidase-treated ancrod (NTA) can be substituted for...
|
|
|
4350625 |
Substance with fibrinolytic activity and method of manufacturing the same
This invention relates to a new fibrinolytic substance and the method of manufacturing the same which can be singly isolated from venom of venomous snakes belonging to the family of Trimeresurus...
|
|
|
4341762 |
Use of snake venoms for treatment of neurological and related disorders
The present invention provides stable compositions of matter including venoms and/or venom fractions extracted from various elapid and viperid snakes, the present compositions of matter having...
|
|
|
4292308 |
Treatment of animals exposed to or subject to exposure to organophosphate animal poisonous nerve agents
A method is provided for treatment of animals exposed to or subject to exposure to organophosphate animal poisonous nerve agents. The animals are injected with an effective amount of modified...
|
|
|
4162303 |
Potency and atoxicity test for modified neurotoxin
A method for proving the potency and atoxicity of modified neurotoxin is provided. A thin sheet of viable cells is provided on a growth substrate. Viability of the sheet of cells is defined as...
|
|
|
4154656 |
Method for determining the fibrinogen content of physiological liquid
What is disclosed is an enzyme system cleaving fibrinogen, said system comprising a fibrinogenase and a water-soluble polysaccharide.
|
|
|
4145185 |
Reagents for screening tests and bioassay of von Willebrand's factor (platelet aggregating factor) in blood plasmas
Screening tests and bioassay of von Willebrand's factor (platelet aggregating factor) in human and animal blood plasma are effected using a reagent of blood platelets and snake venom having a...
|
|
|
4126676 |
Modified neurotoxin derived from Naja genus snake venom
The present invention relates to a composition, a process of production thereof, and a method for treatment of neurological diseases, and especially to the treatment of such diseases as amyotropic...
|
|
|
4027012 |
Process for the extraction of components having anticoagulant activity "in vivo" from snake venoms and products obtained
A process for extracting and isolating from snake venoms the enzymatic component having "in vitro" coagulant activity and "in vivo" anticoagulant activity from the other components having "in...
|
|
|
4012502 |
Snake venom inhibitor material and method of purification
A material extracted from snakes such as snake serum is purified to obtain an inhibitor for snake venom toxicity and/or proteolytic enzymes. Snake serum is treated to obtain a useful therapeutic...
|
|
|
3947575 |
Peptides as argiotensin converting enzyme inhibitors
Disclosed herein is a process for the utilization of certain peptides as angiotensin converting enzyme inhibitors.
|
|
|
3888977 |
Modified neurotoxin
Neurotoxic snake venom is detoxified, e.g., by oxygenation, to form an atoxic, neurotropically active therapeutic composition. The venom must be at least in part derived from the genus Bungarus,...
|
|
|
3879369 |
Anti-coagulant isolation from malayan pit viper using affinity chromatography
A process for the purification and isolation of the thrombin-like fraction of the venom of the Malayan pit viper is described. The simple process uses affinity chromatography for the fractionation...
|
|
|
3869548 |
Medicament for the treatment of disorders of the eye
Method of and medicament for the treatment of disorders of the eye, namely, diabetic retinopathy and degenerative maculation of the eye wherein doses containing heparin in combination with...
|
|
|
3761586 |
HEMOSTATIC AGENT AND THE PROCESS OF PREPARING SAME
The hemostatic agent of the present invention is obtained by the following process: An aqueous solution of Trimeresurus okinavensis venom is treated with almost the same volume of an organic...
|
|
|
3314851 |
Process for reducing the toxicity of poisons
|
|
|
3819831 |
Title is not available
|
|
|
3819605 |
Title is not available
|
|
|
3743722 |
Title is not available
|
|
|
3711376 |
Title is not available
|
|
|
3657416 |
Title is not available
|